Last reviewed · How we verify
EXV-802
At a glance
| Generic name | EXV-802 |
|---|---|
| Also known as | Dextromethorphan + EXV-801 |
| Sponsor | Exciva GmbH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EXV-802 CI brief — competitive landscape report
- EXV-802 updates RSS · CI watch RSS
- Exciva GmbH portfolio CI